Earning Preview: Sociedad Quimica Y Minera De Chile SA this quarter’s revenue is expected to increase by 86.68%, and institutional views are bullish

Earnings Agent11-11

Abstract

Sociedad Quimica Y Minera De Chile SA will report quarterly results on November 18, 2026 after-market; the company’s upcoming print is set against a prior quarter of substantial margin recovery and a consensus outlook that implies sharp year-over-year gains in revenue and earnings per share.

Market Forecast

Consensus for the current quarter calls for revenue of 2.18 billion US dollars, up 86.68% year over year, adjusted EPS of 2.02, up 209.78% year over year, and EBIT of 938.67 million US dollars, up 229.79% year over year; forecasted gross margin and net margin are not provided by the market’s aggregated estimates. The main business remains concentrated in higher-value products, with management and consensus attention anchored on sustaining margin quality while delivering year-over-year expansion in revenue and earnings. The most promising segment is lithium and derivatives, which generated 1.19 billion US dollars last quarter; year-over-year segment growth was not disclosed, though the segment’s scale suggests it will again be the principal driver of the expected top-line increase.

Last Quarter Review

The previous quarter delivered revenue of 2.47 billion US dollars, a gross profit margin of 51.04%, GAAP net profit attributable to shareholders of 660.00 million US dollars, a net profit margin of 26.74%, and adjusted EPS information was not provided; company-reported EPS was 2.31 and increased 645.16% year over year. A notable financial highlight was the sharp quarter-on-quarter improvement in profitability, with net profit up 80.96% on a sequential basis, reflecting a restored margin profile in tandem with stronger throughput. On the business mix, lithium and derivatives contributed 1.19 billion US dollars, or approximately two-thirds of total revenue; iodine and derivatives contributed 275.90 million US dollars, specialty plant nutrition 239.00 million US dollars, potassium 34.40 million US dollars, industrial chemicals 18.90 million US dollars, and other products and services 6.30 million US dollars; year-over-year dynamics by segment were not disclosed, while total company revenue rose 136.74% year over year and exceeded prior consensus by 176.48 million US dollars.

Current Quarter Outlook

Main business trajectory this quarter

The revenue mix from the last reported quarter underscores a dominant contribution from lithium and derivatives, representing 1.19 billion US dollars out of 2.47 billion US dollars, and about 67% of group sales. For the current quarter, consensus points to 2.18 billion US dollars in revenue, implying an 86.68% year-over-year expansion despite a sequential normalization from the prior quarter’s 2.47 billion US dollars. Such a trajectory leaves room for a balanced focus on volume execution and price discipline, with profitability guided by cost capture and product mix rather than anticipated changes in aggregate operating leverage. Absent an explicit forecast for gross or net margin, investors will likely anchor expectations on the last quarter’s 51.04% gross margin and 26.74% net margin as the reference frame for assessing whether the margin recovery seen previously can be sustained.

The sequential pattern implied by the prior quarter’s strong result and the current quarter’s revenue estimate suggests a pathway where aggregate sales remain elevated relative to a year earlier, albeit potentially below the prior period’s absolute level given product allocation and timing of shipments. In this context, operational execution—timely deliveries, consistent quality yields, and unit cost control—becomes critical to preserving the margin profile established last quarter. The company’s prior outperformance versus consensus by 176.48 million US dollars in revenue and the 80.96% quarter-on-quarter net profit uptick frame a high bar for sustaining momentum, yet the current consensus implies that earnings quality can remain robust, with adjusted EPS forecast at 2.02 and EBIT at 938.67 million US dollars.

The mechanics of earnings flow-through this quarter will likely be defined by the interplay between mix and unit economics. The last quarter’s revenue concentration in higher-value segments supports the scale to deliver the 209.78% year-over-year rise in forecast EPS, even without explicit margin guidance in the consensus data. An additional reference point remains the elasticity between revenue and EBIT: a 229.79% year-over-year forecast expansion in EBIT provides a cushion for modest volatility in cost inputs or logistics, while still protecting the earnings profile implied by the 2.02 EPS consensus. In brief, the business trajectory is aligned with a durable earnings cadence, grounded in the prior quarter’s margin recovery and an expected second consecutive quarter of substantial year-over-year growth in revenue and earnings.

Most promising business this quarter

Lithium and derivatives is the largest and most consequential business line by revenue, and last quarter’s 1.19 billion US dollars confirms its centrality to the company’s performance. Although year-over-year growth at the segment level was not disclosed, the current quarter’s consolidated forecasts—revenue up 86.68% year over year, EBIT up 229.79% year over year, and EPS up 209.78% year over year—implicitly rely on the continued resilience of this segment’s contribution. The magnitude of this reliance is visible in the reported mix where lithium accounted for roughly two-thirds of total sales, with the remainder distributed across iodine, specialty plant nutrition, potassium, industrial chemicals, and other activities.

This concentration is not merely a reflection of scale; it also embodies the value-added nature of the product suite that historically correlates with higher gross margins. The last quarter’s 51.04% gross margin provides a baseline to judge the upcoming quarter’s quality of earnings, since any sustained improvement in the lithium portfolio’s realized economics would map directly into EBIT and EPS delivery. Given the consensus trajectory for EBIT and EPS this quarter, the lithium segment’s performance will likely serve as the most sensitive indicator for whether the company meets or exceeds expectations.

Beyond its direct revenue impact, this segment also influences the quarter’s optics for operating metrics such as throughput, average realized selling values, and inventory dynamics. Taken together, these points reinforce why the current quarter’s forecast hinges on lithium and derivatives as the primary growth conduit. A repeat of last quarter’s segment scale, even with modest sequential variance, would still align with the 2.18 billion US dollars revenue consensus and the accompanying year-over-year growth implied in the aggregated forecast.

Stock price sensitivity factors this quarter

Share-price reaction around the print will likely key off a narrow set of measurable items: revenue delivery versus the 2.18 billion US dollars consensus, any disclosed gross margin relative to the prior quarter’s 51.04%, and the relationship between reported EPS and the 2.02 adjusted EPS expectation. In the last quarter, the company demonstrated the ability to outperform on revenue by 176.48 million US dollars and to improve sequential net profit by 80.96%, which recalibrated market expectations upward. As a result, execution missteps—such as lower-than-anticipated volume recognition in the quarter, or adverse product mix that compresses margin—would have a visible mark-to-market effect given the scale of expectations embedded in EBIT and EPS.

In a symmetrical sense, upside sensitivity may be most pronounced if reported EBIT exceeds 938.67 million US dollars and if the company provides visibility on sustained margin strength comparable to, or better than, the 51.04% reference gross margin. Investors are likely to pay particular attention to any commentary on shipping cadence, cost trajectories, and the revenue mix, since these elements directly reconcile to EBIT flow-through and EPS realization against the 2.02 marker. While the consensus lacks an explicit current-quarter margin forecast, the street’s emphasis on earnings quality means even small deviations in mix or cost capture will be scrutinized for their implication on EBIT leverage.

Another factor that can influence stock price response is the consistency between current-quarter results and the recent trajectory. The last quarter’s year-over-year revenue increase of 136.74% sets a high comparative base. Delivering the forecasted 86.68% year-over-year growth this quarter would affirm the notion that the recent recovery is more than a single-quarter event. Conversely, if reported margins materially trail the last quarter’s levels without a clear counterbalance in volume or price, the market could recalibrate expectations for subsequent quarters. In practice, the stock’s immediate post-print move will likely track the delta versus the 2.18 billion US dollars revenue and 2.02 EPS consensus, with disclosure on margins serving as the tie-breaker for the direction and magnitude of the reaction.

Analyst Opinions

Across recent period coverage, the directional calls have skewed bullish. Within the January 1, 2026 to November 11, 2026 window, there is at least one high-profile upgrade to Buy and no notable Sell calls, yielding a bullish-to-bearish ratio of 100% to 0% among analysts who issued directional ratings. One prominent stance came on August 28, 2026, when a major global bank upgraded the shares to Buy and set a 95 US dollars price target, framing the move around improving fundamentals and a constructive path for earnings delivery. The same period also included a well-known European institution maintaining a neutral stance, but this does not alter the directional balance, which remains clearly supportive.

These bullish perspectives dovetail with the consensus numbers for the current quarter: revenue of 2.18 billion US dollars, adjusted EPS of 2.02, and EBIT of 938.67 million US dollars, representing year-over-year gains of 86.68%, 209.78%, and 229.79%, respectively. Analysts citing a constructive view emphasize the magnitude of year-over-year growth embedded in the forecast, the restored margins evidenced last quarter, and the concentration of sales in the high-value lithium and derivatives portfolio that accounted for 1.19 billion US dollars last quarter. The implied message is consistent: if the company aligns reported results with the consensus on revenue and EPS while holding margins near the prior quarter’s levels, the path for positive estimate revisions and favorable stock reaction remains open.

The bullish camp also highlights the recent pattern of outperformance. The last quarter’s revenue exceeded consensus by 176.48 million US dollars, and the quarter-on-quarter net profit growth of 80.96% established a clear earnings recovery. In their framing, the upcoming quarter’s feasibility is anchored in the already-demonstrated capacity to deliver, with a focus on execution details rather than structural shifts. They point to the synergy between the revenue mix and the expected EBIT of 938.67 million US dollars as a core argument supporting the Buy thesis across the near-term window.

On a granular level, bullish analysts will be watching three tests: whether revenue prints at or above 2.18 billion US dollars; whether EPS meets or exceeds the 2.02 expectation; and whether the company communicates margin resilience in line with last quarter’s 51.04% gross margin and 26.74% net margin. Even without explicit margin guidance in the consensus dataset, an outcome that delivers on these three fronts would, in their view, validate the stronger stance taken since late August 2026. By contrast, the neutral voices tend to center on balancing the prior quarter’s exceptional growth base with the need for a consistent cadence of delivery, but they stop short of an outright negative call and thus do not shift the directional ratio away from bullish.

In synthesizing these opinions, the dominant institutional narrative is that the company’s last quarter created a credible baseline, and the current quarter’s consensus embeds robust year-over-year growth that is achievable under steady execution. With lithium and derivatives positioned as the principal revenue engine at 1.19 billion US dollars last quarter, the alignment between mix and earnings is clear enough to sustain constructive forecasts for revenue and EBIT. The majority view is therefore to expect a solid result relative to consensus, provided margin quality remains intact and revenue recognition tracks the anticipated cadence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment